897 related articles for article (PubMed ID: 9293187)
21. Role of the Water-Metal Ion Bridge in Quinolone Interactions with
Carter HE; Wildman B; Schwanz HA; Kerns RJ; Aldred KJ
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769202
[TBL] [Abstract][Full Text] [Related]
22. A 2.8 Å Structure of Zoliflodacin in a DNA Cleavage Complex with
Morgan H; Lipka-Lloyd M; Warren AJ; Hughes N; Holmes J; Burton NP; Mahenthiralingam E; Bax BD
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675148
[TBL] [Abstract][Full Text] [Related]
23. Effects of ciprofloxacin on plasmid DNA supercoiling of Escherichia coli topoisomerase I and gyrase mutants.
Aleixandre V; Herrera G; Urios A; Blanco M
Antimicrob Agents Chemother; 1991 Jan; 35(1):20-3. PubMed ID: 1849710
[TBL] [Abstract][Full Text] [Related]
24. Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance.
Aldred KJ; McPherson SA; Wang P; Kerns RJ; Graves DE; Turnbough CL; Osheroff N
Biochemistry; 2012 Jan; 51(1):370-81. PubMed ID: 22126453
[TBL] [Abstract][Full Text] [Related]
25. Analysis of mutational patterns in quinolone resistance-determining regions of GyrA and ParC of clinical isolates.
Ostrer L; Khodursky RF; Johnson JR; Hiasa H; Khodursky A
Int J Antimicrob Agents; 2019 Mar; 53(3):318-324. PubMed ID: 30582984
[TBL] [Abstract][Full Text] [Related]
26. [DNA supercoiling and topoisomerases in Escherichia coli].
Gómez-Eichelmann MC; Camacho-Carranza R
Rev Latinoam Microbiol; 1995; 37(3):291-304. PubMed ID: 8850348
[TBL] [Abstract][Full Text] [Related]
27. Ciprofloxacin and the fluoroquinolones. New concepts on the mechanism of action and resistance.
Fisher LM; Lawrence JM; Josty IC; Hopewell R; Margerrison EE; Cullen ME
Am J Med; 1989 Nov; 87(5A):2S-8S. PubMed ID: 2574005
[TBL] [Abstract][Full Text] [Related]
28. Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.
Pan XS; Yague G; Fisher LM
Antimicrob Agents Chemother; 2001 Nov; 45(11):3140-7. PubMed ID: 11600369
[TBL] [Abstract][Full Text] [Related]
29. Type II topoisomerases as targets for quinolone antibacterials: turning Dr. Jekyll into Mr. Hyde.
Anderson VE; Osheroff N
Curr Pharm Des; 2001 Mar; 7(5):337-53. PubMed ID: 11254893
[TBL] [Abstract][Full Text] [Related]
30. Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries.
Anderson VE; Zaniewski RP; Kaczmarek FS; Gootz TD; Osheroff N
J Biol Chem; 1999 Dec; 274(50):35927-32. PubMed ID: 10585479
[TBL] [Abstract][Full Text] [Related]
31. A class of gyrase mutants of Salmonella typhimurium show quinolone-like lethality and require rec functions for viability.
Garí E; Figueroa-Bossi N; Blanc-Potard AB; Spirito F; Schmid MB; Bossi L
Mol Microbiol; 1996 Jul; 21(1):111-22. PubMed ID: 8843438
[TBL] [Abstract][Full Text] [Related]
32. Action of quinolones against Staphylococcus aureus topoisomerase IV: basis for DNA cleavage enhancement.
Anderson VE; Zaniewski RP; Kaczmarek FS; Gootz TD; Osheroff N
Biochemistry; 2000 Mar; 39(10):2726-32. PubMed ID: 10704224
[TBL] [Abstract][Full Text] [Related]
33. Roles of topoisomerases in maintaining steady-state DNA supercoiling in Escherichia coli.
Zechiedrich EL; Khodursky AB; Bachellier S; Schneider R; Chen D; Lilley DM; Cozzarelli NR
J Biol Chem; 2000 Mar; 275(11):8103-13. PubMed ID: 10713132
[TBL] [Abstract][Full Text] [Related]
34. A mutation in yeast TOP2 homologous to a quinolone-resistant mutation in bacteria. Mutation of the amino acid homologous to Ser83 of Escherichia coli gyrA alters sensitivity to eukaryotic topoisomerase inhibitors.
Hsiung Y; Elsea SH; Osheroff N; Nitiss JL
J Biol Chem; 1995 Sep; 270(35):20359-64. PubMed ID: 7657608
[TBL] [Abstract][Full Text] [Related]
35. Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group.
Lu T; Zhao X; Drlica K
Antimicrob Agents Chemother; 1999 Dec; 43(12):2969-74. PubMed ID: 10582891
[TBL] [Abstract][Full Text] [Related]
36. DNA gyrase and topoisomerase IV: biochemical activities, physiological roles during chromosome replication, and drug sensitivities.
Levine C; Hiasa H; Marians KJ
Biochim Biophys Acta; 1998 Oct; 1400(1-3):29-43. PubMed ID: 9748489
[TBL] [Abstract][Full Text] [Related]
37. Mode of action of the quinolone antimicrobial agents: review of recent information.
Hooper DC; Wolfson JS
Rev Infect Dis; 1989; 11 Suppl 5():S902-11. PubMed ID: 2549608
[TBL] [Abstract][Full Text] [Related]
38. The Current Case of Quinolones: Synthetic Approaches and Antibacterial Activity.
Naeem A; Badshah SL; Muska M; Ahmad N; Khan K
Molecules; 2016 Mar; 21(4):268. PubMed ID: 27043501
[TBL] [Abstract][Full Text] [Related]
39. Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition.
Hoshino K; Kitamura A; Morrissey I; Sato K; Kato J; Ikeda H
Antimicrob Agents Chemother; 1994 Nov; 38(11):2623-7. PubMed ID: 7872758
[TBL] [Abstract][Full Text] [Related]
40. Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro.
Heaton VJ; Ambler JE; Fisher LM
Antimicrob Agents Chemother; 2000 Nov; 44(11):3112-7. PubMed ID: 11036032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
